Huang Q, Hu B, Zhang P, Yuan Y, Yue S, Chen X
Mol Cancer. 2025; 24(1):24.
PMID: 39825376
PMC: 11740516.
DOI: 10.1186/s12943-024-02219-0.
Ng R, Lin Z, Zhang Y, Ti S, Javed A, Wong J
Sci Adv. 2024; 10(29):eadm9577.
PMID: 39028815
PMC: 11259169.
DOI: 10.1126/sciadv.adm9577.
Woodcock D, Sahli A, Teslo R, Bhandari V, Gruber A, Ziubroniewicz A
Cell Genom. 2024; 4(3):100511.
PMID: 38428419
PMC: 10943594.
DOI: 10.1016/j.xgen.2024.100511.
Terron-Bautista J, Martinez-Sanchez M, Lopez-Hernandez L, Vadusevan A, Garcia-Dominguez M, Williams R
bioRxiv. 2024; .
PMID: 38328138
PMC: 10849543.
DOI: 10.1101/2024.01.22.576640.
Yu J, Lim J, Song W
Biomedicines. 2024; 12(1).
PMID: 38255286
PMC: 10813541.
DOI: 10.3390/biomedicines12010181.
A cyclin D1 intrinsically disordered domain accesses modified histone motifs to govern gene transcription.
Jiao X, Di Sante G, Casimiro M, Tantos A, Ashton A, Li Z
Oncogenesis. 2024; 13(1):4.
PMID: 38191593
PMC: 10774418.
DOI: 10.1038/s41389-023-00502-1.
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Markowski M, Taplin M, Aggarwal R, Sena L, Wang H, Qi H
Nat Commun. 2024; 15(1):14.
PMID: 38167882
PMC: 10762051.
DOI: 10.1038/s41467-023-44514-2.
Induction of double-strand breaks with the non-steroidal androgen receptor ligand flutamide in patients on androgen suppression: a study protocol for a randomized, double-blind prospective trial.
Lee E, Coulter J, Mishra A, Caramella-Pereira F, Demarzo A, Rudek M
Trials. 2023; 24(1):809.
PMID: 38104131
PMC: 10725600.
DOI: 10.1186/s13063-023-07838-4.
RAD54L2-mediated DNA damage avoidance pathway specifically preserves genome integrity in response to topoisomerase 2 poisons.
Zhang H, Xiong Y, Sun Y, Park J, Su D, Feng X
Sci Adv. 2023; 9(49):eadi6681.
PMID: 38055811
PMC: 10699775.
DOI: 10.1126/sciadv.adi6681.
Using energy to go downhill-a genoprotective role for ATPase activity in DNA topoisomerase II.
Bandak A, Blower T, Nitiss K, Shah V, Nitiss J, Berger J
Nucleic Acids Res. 2023; 52(3):1313-1324.
PMID: 38038260
PMC: 10853770.
DOI: 10.1093/nar/gkad1157.
Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against (Fusion)-Driven and Non-Fusion-Driven Prostate Cancer.
Raina K, Kandhari K, Kant R, Prasad R, Mishra N, Maurya A
Cancers (Basel). 2023; 15(20).
PMID: 37894421
PMC: 10605633.
DOI: 10.3390/cancers15205054.
To Break or Not to Break: The Role of TOP2B in Transcription.
Cowell I, Casement J, Austin C
Int J Mol Sci. 2023; 24(19).
PMID: 37834253
PMC: 10573011.
DOI: 10.3390/ijms241914806.
Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs.
Choi H, Chang J
Int J Mol Sci. 2023; 24(17).
PMID: 37686423
PMC: 10487969.
DOI: 10.3390/ijms241713618.
Trinity of inflammation, innate immune cells and cross-talk of signalling pathways in tumour microenvironment.
Attiq A, Afzal S
Front Pharmacol. 2023; 14:1255727.
PMID: 37680708
PMC: 10482416.
DOI: 10.3389/fphar.2023.1255727.
Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire.
Nabavi N, Mahdavi S, Afshar Ardalan M, Chamanara M, Mosaed R, Lara A
Biomedicines. 2023; 11(7).
PMID: 37509723
PMC: 10377678.
DOI: 10.3390/biomedicines11072084.
The potential role of the microbiota in prostate cancer pathogenesis and treatment.
Pernigoni N, Guo C, Gallagher L, Yuan W, Colucci M, Troiani M
Nat Rev Urol. 2023; 20(12):706-718.
PMID: 37491512
DOI: 10.1038/s41585-023-00795-2.
Targeting the Androgen Signaling Axis in Prostate Cancer.
Dai C, Dehm S, Sharifi N
J Clin Oncol. 2023; 41(26):4267-4278.
PMID: 37429011
PMC: 10852396.
DOI: 10.1200/JCO.23.00433.
ERα-associated translocations underlie oncogene amplifications in breast cancer.
Lee J, Jung Y, Cheong T, Espejo Valle-Inclan J, Chu C, Gulhan D
Nature. 2023; 618(7967):1024-1032.
PMID: 37198482
PMC: 10307628.
DOI: 10.1038/s41586-023-06057-w.
PARP inhibitors in metastatic prostate cancer.
Taylor A, Kosoff D, Emamekhoo H, Lang J, Kyriakopoulos C
Front Oncol. 2023; 13:1159557.
PMID: 37168382
PMC: 10165068.
DOI: 10.3389/fonc.2023.1159557.
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
Denmeade S, Sena L, Wang H, Antonarakis E, Markowski M
Oncologist. 2023; 28(6):465-473.
PMID: 37027449
PMC: 10243791.
DOI: 10.1093/oncolo/oyad055.